Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Redhill Biopharma Ltd. for the month of December 2025. The filing primarily serves to incorporate by reference unaudited pro forma condensed consolidated financial information (Exhibit 99.1) related to definitive agreements between Redhill Biopharma Ltd. and Cumberland Pharmaceuticals Inc., originally described in a Current Report on Form 6-K filed on October 20, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document references unaudited pro forma financial information contained in Exhibit 99.1 but does not reproduce the data within the body of this report.
Material Changes
The material change highlighted in this filing is the inclusion of pro forma financial data reflecting the strategic transaction with Cumberland Pharmaceuticals Inc. No specific comparative financial metrics against prior periods are provided in this text.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the potential impact of the strategic transaction with Cumberland Pharmaceuticals Inc. Management notes that these statements are subject to substantial risks and uncertainties, including:
- The risk that the strategic transaction will not deliver currently anticipated benefits to the Company or the global Talicia business.
- The risk that assumptions made in preparing the unaudited pro forma financial information are incorrect.
- General uncertainties beyond the Company's control that may cause actual results to differ materially from projections.
The Company assumes no obligation to update these forward-looking statements unless required by law.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific unaudited pro forma condensed consolidated financial figures.
- Verify the terms of the definitive agreements with Cumberland Pharmaceuticals Inc. referenced in the October 20, 2025 filing.
- Assess the assumptions underlying the pro forma financial information for reasonableness.
- Consult the Annual Report on Form 20-F filed on April 10, 2025, for detailed risk factors.